Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.

Because there is limited information about suppression of virus loads (determined by current "ultrasensitive" assays) in patients receiving nucleoside reverse-transcriptase inhibitors (NRTIs) alone, we reviewed our experience in clinical practice with patients who had virus loads of <25 copies/mL after >1 year of treatment with dual NRTIs.